Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
10/19/2000 | WO2000061541A2 Pharmaceutical compounds |
10/19/2000 | WO2000061539A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
10/19/2000 | WO2000061234A1 Combinations of gaba analogs and tricyclic compounds to treat depression |
10/19/2000 | WO2000061231A2 Medical use |
10/19/2000 | WO2000061189A2 Water-soluble compositions of bioactive lipophilic compounds |
10/19/2000 | WO2000061188A1 Sodium channel blocker compositions and the use thereof |
10/19/2000 | WO2000061180A2 Products and methods for treating ptp lar related diseases |
10/19/2000 | WO2000061176A2 Treatment of multiple sclerosis with a combination of interferon and growth hormone |
10/19/2000 | WO2000061171A2 Uses of mammalian ox2 protein and related reagents |
10/19/2000 | WO2000061170A2 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid) |
10/19/2000 | WO2000061164A1 Modulation of excitable tissue function by peripherally administered erythropoietin |
10/19/2000 | WO2000061159A1 MEDICAMENT FOR INHIBITING NF-λB |
10/19/2000 | WO2000061156A2 Methods of treating schizophrenia |
10/19/2000 | WO2000061152A1 Management of pain after joint surgery |
10/19/2000 | WO2000061147A1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
10/19/2000 | WO2000061138A1 Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
10/19/2000 | WO2000061131A1 Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus angelicae containing same |
10/19/2000 | WO2000061129A2 S-hydroxynefazodone |
10/19/2000 | WO2000061128A2 R-hydroxynefazodone |
10/19/2000 | WO2000061125A2 Osanetant in the treatment of mood disorders |
10/19/2000 | WO2000061094A1 Antiperspirant compositions |
10/19/2000 | WO2000041505A3 Anthranilic acid derivatives |
10/19/2000 | WO2000037103A3 Compounds for intracellular delivery of therapeutic moieties to nerve cells |
10/19/2000 | WO2000029551A3 Cells, culture methods, and their use in autologous transplantation therapy |
10/19/2000 | WO2000029550A9 Low oxygen culturing of central nervous system progenitor cells |
10/19/2000 | WO2000012720A8 Elongase genes and uses thereof |
10/19/2000 | WO2000007996A8 Pyrazoles as estrogen receptor modulators |
10/19/2000 | DE19917930A1 Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity |
10/19/2000 | DE19917505A1 Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives |
10/19/2000 | DE19915602A1 3-Amino-4-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung 3-amino-4-arylpropan-1-ol-derivatives, their preparation and use |
10/19/2000 | DE19915601A1 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung 3-amino-3-arylpropan-1-ol-derivatives, their preparation and use |
10/19/2000 | DE19915465A1 Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten Using a Caspase inhibitor for the inhibition of proliferation of cells and using one or more caspase inhibitor / s for the treatment of diseases based on lymphocyte hyperproliferation or for suppression of an immune response by lymphocytes |
10/19/2000 | CA2383940A1 Modulation of excitable tissue function by peripherally administered erythropoietin |
10/19/2000 | CA2371223A1 49 human secreted proteins |
10/19/2000 | CA2371172A1 50 human secreted proteins |
10/19/2000 | CA2370767A1 49 human secreted proteins |
10/19/2000 | CA2370523A1 49 human secreted proteins |
10/19/2000 | CA2370425A1 Pharmaceutical compounds |
10/19/2000 | CA2370267A1 Prodrugs of thrombin inhibitors |
10/19/2000 | CA2370039A1 Apoptosis-associated gene |
10/19/2000 | CA2369981A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
10/19/2000 | CA2369822A1 Novel human voltage-gated potassium channel |
10/19/2000 | CA2369732A1 R-hydroxynefazodone |
10/19/2000 | CA2369695A1 Agent for treating neuropathic pain |
10/19/2000 | CA2369691A1 4-hydroxypiperidine derivatives having antiarrhythmic effect |
10/19/2000 | CA2369638A1 Use of osanetant in the production of medicaments used to treat mood disorders |
10/19/2000 | CA2369629A1 Method to type prion proteins |
10/19/2000 | CA2369619A1 Caspase inhibitors and the use thereof |
10/19/2000 | CA2369472A1 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid) |
10/19/2000 | CA2369454A1 Uses of mammalian ox2 protein and related reagents |
10/19/2000 | CA2369439A1 Methods of treating schizophrenia |
10/19/2000 | CA2369378A1 Low-molecular inhibitors of complement proteases |
10/19/2000 | CA2369301A1 Management of pain after joint surgery |
10/19/2000 | CA2369225A1 S-hydroxynefazodone |
10/19/2000 | CA2368840A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
10/19/2000 | CA2367494A1 Combinations of gaba analogs and tricyclic compounds to treat depression |
10/19/2000 | CA2365945A1 Products and methods for treating ptp lar related diseases |
10/19/2000 | CA2365918A1 49 human secreted proteins |
10/19/2000 | CA2365917A1 Bone morphogenic proteins |
10/19/2000 | CA2365910A1 Human proteins and polynucleotides encoding them |
10/19/2000 | CA2365623A1 Tyrosine kinase substrate (tks) proteins |
10/19/2000 | CA2365070A1 Combined treatment of multiple sclerosis |
10/19/2000 | CA2364690A1 Novel transduction molecules and methods for using same |
10/18/2000 | EP1044970A1 Aminotriazole compounds, process for their preparation and pharmaceutical compositions containing them |
10/18/2000 | EP1044605A1 Gene mutant animals |
10/18/2000 | EP1044218A1 Nucleic acids encoding transferrin receptor-like proteins and products related thereto |
10/18/2000 | EP1044215A1 Anti-inflammatory phenylalanine derivatives |
10/18/2000 | EP1044210A1 Human dendriac and brainiac-3 |
10/18/2000 | EP1044206A1 Prodrugs of naaladase inhibitors |
10/18/2000 | EP1044203A1 3'-epimeric k-252a derivatives |
10/18/2000 | EP1044202A1 1'- 4- 1- (4-fluorophenyl)- 1h-indole-3-yl] -1-butyl]-spiro isobenzofuran- 1(3h),4'- piperidine] hydrohalogenides |
10/18/2000 | EP1044201A1 3-substituted adenines via2-thioxanthines |
10/18/2000 | EP1044189A1 Aryl fused azapolycyclic compounds |
10/18/2000 | EP1044186A1 Substituted 2-benzylamino-2-phenyl-acetamide compounds |
10/18/2000 | EP1044024A1 Use of pigmented retinal epithelial cells for creation of an immune privilege site |
10/18/2000 | EP1044023A1 A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia |
10/18/2000 | EP1044020A2 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products |
10/18/2000 | EP1044009A2 Methods and compositions employing red rice fermentation products |
10/18/2000 | EP1043999A1 Novel substituted pyridine compounds useful as modulators of acetylcholine receptors |
10/18/2000 | EP1043998A1 USE OF PYRAZOLO 3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS |
10/18/2000 | EP1043996A2 Treatment of dyskinesias |
10/18/2000 | EP1043994A1 Method for treating multiple sclerosis |
10/18/2000 | EP1043991A1 Treatment for alzheimer's disease |
10/18/2000 | EP1043987A1 Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host |
10/18/2000 | EP1043983A1 Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system |
10/18/2000 | EP1043980A2 Method of reducing craving in mammals |
10/18/2000 | EP1043941A1 Revitalisation formulation |
10/18/2000 | EP0633886B1 Pharmaceutically active bicyclic-heterocyclic amines |
10/18/2000 | CN1270592A Spiroazabicyclic heterocyclic compounds |
10/18/2000 | CN1270585A Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
10/18/2000 | CN1270528A Nootropic agent |
10/18/2000 | CN1270520A Treatment of oppositional defiant disorder |
10/18/2000 | CN1270169A Benzopyrane derivatives and preparation thereof |
10/18/2000 | CN1270163A 3-amino-3-aryl-1-alcohol derivatives and preparation and use thereof |
10/18/2000 | CN1270162A 3-amino-3-aryl-1-alcohol derivatives and preparation and use thereof |
10/18/2000 | CN1270045A Chinese patent medicine for treating hemicrania-type diseases caused by cerebral vessal |
10/18/2000 | CN1270043A Medicine for treating hemicrania |
10/18/2000 | CN1270042A 'Yuxianan' capsule |
10/18/2000 | CN1270029A Thebaic analgesic with controllable releasement of active content |
10/18/2000 | CN1270028A Analgesic with controlled releasement of active content |